- Home
- COCP vs NEUP Comparison
COCP vs NEUP Comparison
Compare COCP & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCP
- NEUP
- Stock Information
- Founded
- COCP 2006
- NEUP 1996
- Country
- COCP United States
- NEUP United States
- Employees
- COCP N/A
- NEUP N/A
- Industry
- COCP Biotechnology: Pharmaceutical Preparations
- NEUP
- Sector
- COCP Health Care
- NEUP
- Exchange
- COCP Nasdaq
- NEUP Nasdaq
- Market Cap
- COCP 15.4M
- NEUP 12.7M
- IPO Year
- COCP N/A
- NEUP N/A
- Fundamental
- Price
- COCP $1.07
- NEUP $15.52
- Analyst Decision
- COCP Strong Buy
- NEUP Strong Buy
- Analyst Count
- COCP 1
- NEUP 2
- Target Price
- COCP $6.00
- NEUP $28.00
- AVG Volume (30 Days)
- COCP 269.2K
- NEUP 93.2K
- Earning Date
- COCP 11-12-2025
- NEUP 11-15-2025
- Dividend Yield
- COCP N/A
- NEUP N/A
- EPS Growth
- COCP N/A
- NEUP N/A
- EPS
- COCP N/A
- NEUP N/A
- Revenue
- COCP N/A
- NEUP $15,649,448.00
- Revenue This Year
- COCP N/A
- NEUP N/A
- Revenue Next Year
- COCP N/A
- NEUP N/A
- P/E Ratio
- COCP N/A
- NEUP N/A
- Revenue Growth
- COCP N/A
- NEUP N/A
- 52 Week Low
- COCP $1.02
- NEUP $2.90
- 52 Week High
- COCP $3.26
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- COCP 32.57
- NEUP 53.94
- Support Level
- COCP $1.02
- NEUP $14.64
- Resistance Level
- COCP $1.09
- NEUP $17.90
- Average True Range (ATR)
- COCP 0.07
- NEUP 2.17
- MACD
- COCP -0.01
- NEUP -0.31
- Stochastic Oscillator
- COCP 17.24
- NEUP 46.59
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.